Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Holding TVTX?
Track your performance easily
TVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.12 - $20.33
Previous Close$18.81
Volume1.49M
Average Volume (3M)1.98M
Market Cap
$1.64B
Enterprise Value$1.76B
Total Cash (Recent Filing)$277.44M
Total Debt (Recent Filing)$402.43M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 03, 2025EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding78,049,928
10 Day Avg. Volume1,507,487
30 Day Avg. Volume1,976,378
Standard Deviation0.18
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-45.80
Price to Sales (P/S)6.67
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.66
Enterprise Value/Gross Profit13.17
Enterprise Value/Ebitda-7.53
Forecast
1Y Price Target
$26.50Price Target Upside40.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Travere Therapeutics News
PremiumCompany Announcements
Travere Therapeutics Boosts Sales with FILSPARI Approval
Bulls Say, Bears Say
Bulls Say
Market ExpansionFilspari's launch in Germany and Austria through commercial partner CSL Vifor, along with temporary marketing approval in Switzerland, highlights its growing international presence.
Regulatory ProgressThe FDA is motivated to accept proteinuria as a validated surrogate endpoint in FSGS, strengthening the case for Filspari's potential approval.
Sales PerformanceFilspari's net sales reached $35.6M with a remarkable 343% year-over-year growth, indicating strong market acceptance and demand.
Bears Say
Clinical Study ConcernsThe primary eGFR data from the DUPLEX study did not achieve statistical significance, raising doubts about the reliability of secondary endpoints.
Manufacturing And Supply IssuesTravere paused patient enrollment for the Phase 3 HARMONY study due to challenges in scaling up the manufacturing process, which affects the supply of the necessary enzyme replacement therapy.
Regulatory ChallengesThe FDA may request additional data or evidence for Filspari's mechanism of action, which could potentially require another clinical trial.
---
Ownership Overview
1.33% Insiders
19.96% Mutual Funds
41.52% Other Institutional Investors
24.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $20.33 in the past 12 months.
What is Travere Therapeutics’s market cap?
Currently, no data Available
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 72 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.669 by -$0.031.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -$0.64.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 87,034,300 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.669. Following the earnings report the stock price went down -1.464%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Among the largest hedge funds holding Travere Therapeutics’s share is Woodline Partners LP. It holds Travere Therapeutics’s shares valued at 61M.
---
Travere Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.50 (40.88% Upside)
$26.50 (40.88% Upside)
Blogger Sentiment
Neutral
TVTX Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
194.36%
12-Months-Change
Fundamentals
Return on Equity
-279.94%
Trailing 12-Months
Asset Growth
-39.44%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics is focused on developing therapies for rare kidney and metabolic disorders. The biopharmaceutical company's products include FILSPARI (sparsentan), and Thiola and Thiola EC (tiopronin tablets).
---
TVTX Earnings Call
Q3 2024
0:00 / 0:00
---
TVTX Stock 12 Month Forecast
Average Price Target
$26.50
▲(40.88% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Fate Therapeutics
―
Arvinas Holding Company
―
Allogene Therapeutics
―
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+22.29%
reiterated a buy rating 2 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +22.29% per trade.
---